TABLE 1
FROM:
The impact of a supplementary medication review and counselling service within the oncology outpatient setting
H Read, S Ladds, B Rhodes, D Brown and J Portlock
BACK TO ARTICLETable 1. Nature of the chemotherapy regimes and treatment modes used in the control and clinic arms of the study
| Regimen | Control arm (no. of patients) | Clinic arm (no. of patients) |
|---|---|---|
| Adjuvant FEC 60 mg m-2 | 8 | 15 |
| Adjuvant EC 60 | 6 | 5 |
| Adjuvant paclitaxel | 5 | — |
| Adjuvant docetaxel | — | 2 |
| Adjuvant FEC 75 mg m-2 | 17 | 26 |
| Adjuvant AC | — | 1 |
| Adjuvant EC 75 | — | 3 |
| Neo-adjuvant FEC 75 | 1 | 2 |
| Metastatic epirubicin+docetaxel | 2 | — |
| Metastatic docetaxel | 10 | 10 |
| Metastatic trastuzumab | 13 | 2 |
| Metastatic vinorelbine | 3 | 2 |
| Metastatic EC 60 | 3 | — |
| Metastatic capecitabine | 2 | — |
| Metastatic docetaxel and trastuzumab | — | 2 |
| Chemotherapy cycle number | Control arm | Clinic arm |
|---|---|---|
| 2 | 53 | 53 |
| 3 | 15 | 13 |
| 4 | 2 | 4 |
A=Adriamycin (doxorubicin); C=cyclophosphamide; E=epirubicin; F=fluorouracil.
